Tuberculosis and atypical mycobacterial infections in ruxolitinib-treated patients with primary or secondary myelofibrosis or polycythemia vera.
Aged
Female
Humans
Male
Mycobacterium Infections, Nontuberculous
/ drug therapy
Mycobacterium avium
/ drug effects
Mycobacterium tuberculosis
/ drug effects
Nitriles
Polycythemia Vera
/ drug therapy
Primary Myelofibrosis
/ drug therapy
Protein Kinase Inhibitors
/ therapeutic use
Pyrazoles
/ therapeutic use
Pyrimidines
Tuberculosis
/ drug therapy
Mycobacteria
Mycobacterium avium complex
Mycobacterium tuberculosis
Ruxolitinib
Tuberculosis
Journal
International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
ISSN: 1878-3511
Titre abrégé: Int J Infect Dis
Pays: Canada
ID NLM: 9610933
Informations de publication
Date de publication:
Mar 2019
Mar 2019
Historique:
received:
17
09
2018
revised:
23
12
2018
accepted:
04
01
2019
pubmed:
15
1
2019
medline:
6
5
2019
entrez:
15
1
2019
Statut:
ppublish
Résumé
Ruxolitinib is a JAK-1/JAK-2 inhibitor indicated for the treatment of polycythemia vera and primary or secondary myelofibrosis. Only one patient (0.2%) was diagnosed with tuberculosis among the 485 patients receiving ruxolitinib in the four pivotal trials. Fourteen cases of tuberculosis have since been reported. We observed two (3%) mycobacterial infections (one due to Mycobacterium tuberculosis and one due to Mycobacterium avium complex) in our cohort of 65 patients receiving ruxolitinib. This observation suggests that the rate of mycobacterial infection might be higher than that observed in the pivotal trials and that atypical mycobacterial infections can also occur.
Identifiants
pubmed: 30639623
pii: S1201-9712(19)30012-8
doi: 10.1016/j.ijid.2019.01.002
pii:
doi:
Substances chimiques
Nitriles
0
Protein Kinase Inhibitors
0
Pyrazoles
0
Pyrimidines
0
ruxolitinib
82S8X8XX8H
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
134-136Informations de copyright
Copyright © 2019 The Author(s). Published by Elsevier Ltd.. All rights reserved.